VBIV VBI Vaccines Inc.

1.53
+0.13  (+9%)
Previous Close 1.4
Open 1.43
Price To Book 1.32
Market Cap 102018064
Shares 66,678,473
Volume 1,288,286
Short Ratio
Av. Daily Volume 439,224

SEC filingsSee all SEC filings

  1. 424B5 - Prospectus [Rule 424(b)(5)] 181231068
  2. D - Notice of Exempt Offering of Securities 181224344
  3. 8-K - Current report 181218949
  4. 8-K - Current report 181183631
  5. 8-K - Current report 181172775

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2a 6-month PFS and OS data due 1H 2019.
VBI-1901
Recurrent glioblastoma multiforme (rGBM)
Phase 3 data due mid-2019.
Sci-B-Vac - PROTECT
Hepatitis B vaccine
Final data from the study released May 10, 2018.
VBI-1501
Congenital Cytomegalovirus (CMV)
Phase 3 data due YE 2019.
Sci-B-Vac - CONSTANT
Hepatitis B vaccine

Latest News

  1. VBI Vaccines Announces Pricing of $37.5 Million Public Offering
  2. VBI Vaccines Announces Proposed Public Offering of Common Shares
  3. VBI Vaccines Enters into License and Collaboration Agreement with Brii Biosciences for up to $129 Million plus Royalties to Develop a Functional Cure for Hepatitis B
  4. The Daily Biotech Pulse: Mallinckrodt FDA Verdict, European Cheer For Bristol-Myers Squibb, Morphosys Clinches Licensing Deal
  5. VBI Vaccines Announces Third Quarter 2018 Financial Results and Provides Corporate Update
  6. Research Report Identifies Sorrento Therapeutics, Hurco Companies, Veritiv, Park Electrochemical, VBI Vaccines, and PennantPark Floating Rate Capital with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
  7. VBI Vaccines to Present Initial Data for VBI-1901 in Recurrent Glioblastoma (GBM) Patients at the 2018 Annual Meeting of the Society for Neuro-Oncology (SNO)
  8. VBI Vaccines Completes Vaccination in PROTECT Phase 3 Clinical Study for Sci-B-Vac® Hepatitis B Vaccine
  9. VBI Vaccines’ Late-Breaker Cytomegalovirus Abstract Chosen for Oral Presentation at IDWeek 2018
  10. VBI Vaccines to Present at the Ladenburg Thalmann 2018 Healthcare Conference
  11. VBI Vaccines Announces Formation of New Scientific and Clinical Advisory Boards
  12. VBI Vaccines Announces Second Positive DSMB Review in Phase 1/2a Study of VBI-1901 in Recurrent Glioblastoma (GBM) Patients

SEC Filings

  1. 424B5 - Prospectus [Rule 424(b)(5)] 181231068
  2. D - Notice of Exempt Offering of Securities 181224344
  3. 8-K - Current report 181218949
  4. 8-K - Current report 181183631
  5. 8-K - Current report 181172775
  6. 10-Q - Quarterly report [Sections 13 or 15(d)] 181171422
  7. 8-K - Current report 181136103
  8. 8-K - Current report 181128593
  9. 8-K - Current report 181124094
  10. 8-K - Current report 181106863